LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

Strona główna・Stock List・Pacific Biosciences of California Inc

Pacific Biosciences of California Inc

Closed

SectorHealthcare

1.25 6.84

Buy Sell

Overview

Share price change

24h

Current

Min

1.16

Max

1.26

Key metrics
By Trading Economics
Income	32M -8.3M
Sales	-7.5M 37M
EPS	-0.12
Profit margin	-22.258
Employees	485
EBITDA	509K -38M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	+100% upside

Dividends
By Dow Jones
Next Earnings	6 sie 2026

Market Stats
By TradingEconomics
Market Cap	-124M 357M
Previous open	-5.59
Previous close	1.25

News Sentiment

By Acuity

64%

36%

307 / 345 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

1.13 / N/A Support & Resistance

Pacific Biosciences of California Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

20 maj 2026, 23:31 UTC

Hot Stocks

Stocks to Watch: Intuit, Applied Digital, Osisko, Banzai

20 maj 2026, 22:52 UTC

Major Market Movers

Osisko Shares Fall on Planned Convertible Notes Offering

20 maj 2026, 23:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20 maj 2026, 23:47 UTC

Market Talk

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

20 maj 2026, 23:44 UTC

Earnings

Musk Is In Total Control of SpaceX. The IPO Filing Has Finally Come. -- Barrons.com

20 maj 2026, 23:35 UTC

Market Talk

Gold Edges Lower Amid Slightly Higher U.S. Treasury Yields -- Market Talk

20 maj 2026, 23:30 UTC

Market Talk

Goodman Well-Placed for Earnings Guidance Upgrade -- Market Talk

20 maj 2026, 23:17 UTC

Market Talk

Global Equities Roundup: Market Talk

20 maj 2026, 23:17 UTC

Market Talk

Ryman Healthcare Bull Focusing on Three Areas in FY26 Result -- Market Talk

20 maj 2026, 23:15 UTC

Market Talk

Mainfreight's FY26 Profit Fall May Mask Improving Performance -- Market Talk

20 maj 2026, 23:14 UTC

Earnings

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 4th Update

20 maj 2026, 23:02 UTC

Market Talk

KMD Brands Faces Two Testing Hurdles -- Market Talk

20 maj 2026, 22:57 UTC

Market Talk

Infratil's Other Assets Deserve Attention, Too -- Market Talk

20 maj 2026, 22:57 UTC

Market Talk

Global Energy Roundup: Market Talk

20 maj 2026, 22:57 UTC

Market Talk

Global Equities Roundup: Market Talk

20 maj 2026, 22:51 UTC

Market Talk

Australia Shares Set to Rise, Continue Whipsaw Week -- Market Talk

20 maj 2026, 22:51 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20 maj 2026, 22:27 UTC

Market Talk

SpaceX Says It Has Largest Addressable Market in 'Human History' -- Market Talk

20 maj 2026, 22:14 UTC

Market Talk

Moody's Downgrades Mexico's Sovereign Rating -- Market Talk

20 maj 2026, 22:10 UTC

Earnings

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 3rd Update

20 maj 2026, 22:00 UTC

Earnings

Intuit Stock Falls on Earnings -- and the Company Plans to Cut 17% of Its Workforce -- Barrons.com

20 maj 2026, 21:38 UTC

Earnings

Acquisitions, Mergers, Takeovers

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 2nd Update

20 maj 2026, 21:27 UTC

Earnings

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- Update

20 maj 2026, 21:20 UTC

Earnings

Nvidia CFO: Edge Computing Demand Fell Modestly Due to Higher Memory Prices

20 maj 2026, 21:19 UTC

Earnings

Nvidia Still Uncertain Whether Shipping to China Will Be Allowed, CFO Says

20 maj 2026, 21:18 UTC

Earnings

Nvidia on Track to Start Production Shipments of Vera Rubin in Second Half of This Year, CFO Says

20 maj 2026, 21:17 UTC

Earnings

Nvidia Projects $20B in CPU Revenue This Year, CFO Says

20 maj 2026, 21:17 UTC

Earnings

Nvidia CFO: Every Major Hyperscaler Engaged in Deploying Vera CPU

20 maj 2026, 21:17 UTC

Earnings

Nvidia's Vera CPU Opens New $200B Market, CFO Says

20 maj 2026, 21:16 UTC

Earnings

SpaceX IPO Filing Finally Comes. Mars, Musk, and More Big Things to Watch. -- Barrons.com

Peer Comparison

Price change

Pacific Biosciences of California Inc Forecast

Price Target

By TipRanks

100% upside

12 Months Forecast

Average 2.38 USD 100%

High 3 USD

Low 1.5 USD

Based on 4 Wall Street analysts offering 12 month price targets forPacific Biosciences of California Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

4 ratings

Buy

Hold

Sell

Based on 4 analysts giving stock ratings to Pacific Biosciences of California Inc - Dist in the past 3 months.

Technical Score

By Trading Central

1.13 / N/ASupport & Resistance

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

There is one bearish event.

Sentiment

By Acuity

307 / 345 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Pacific Biosciences of California Inc

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.